trial to assess whether a reduced-dose regimen of apixaban (2.5 mg twice daily) would be noninferior to a full-dose regimen (5.0 mg twice daily) for the prevention of recurrent venous ...

CHICAGO, IL—For patients with active cancer who’ve had venous thromboembolism (VTE), 12-month extended anticoagulation with reduced-dose apixaban is noninferior to the full dose at preventing ...

Participants were randomized to oral apixaban at a reduced dose (2.5 mg) or a full dose (5.0 mg) twice daily for 12 months. The primary outcome was centrally adjudicated fatal or nonfatal ...

One group received standard care, while the other got standard care plus apixaban (2.5 mg twice daily) for three months. After three months, the apixaban group had fewer clot recurrences—24% ...

Please provide your email address to receive an email when new articles are posted on . Continued anticoagulation is recommended for patients with active cancer and/or ongoing cancer treatment.

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.